Clinical trial of tolerability, safety and immunogenicity of influenza inactivated split-vaccine Flu-M in children aged 6 to 17 years
Purpose. To evaluate the tolerability, safety and immunogenicity of influenza inactivated split flu vaccine Flu-M during single immunization of children aged 6 to 17 years.Materials and methods. A multicentre double-blind comparative randomised clinical trial of influenza inactivated split vaccine F...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2024-04-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/1605 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241147344420864 |
|---|---|
| author | A. M. Korolyuk V. N. Kraeva L. A. Zazimko Yu. A. Koromzin E. A. Ruzanova N. N. Savina E. V. Ryskova |
| author_facet | A. M. Korolyuk V. N. Kraeva L. A. Zazimko Yu. A. Koromzin E. A. Ruzanova N. N. Savina E. V. Ryskova |
| author_sort | A. M. Korolyuk |
| collection | DOAJ |
| description | Purpose. To evaluate the tolerability, safety and immunogenicity of influenza inactivated split flu vaccine Flu-M during single immunization of children aged 6 to 17 years.Materials and methods. A multicentre double-blind comparative randomised clinical trial of influenza inactivated split vaccine Flu-M for immunisation of children aged 6 to 17 years (the reference agent – Ultrix vaccine) was conducted. Children aged 12 to 17 years inclusive (300 children) were studied at stage I, and children aged 6 to 12 years (300 children) at stage II. Volunteers of each age category were randomised 1:1 into 2 groups comparable in sex and age, one was vaccinated with Flu-M vaccine and the other with Ultrix vaccine. The follow-up, including various laboratory and clinical tests, lasted for 28 days from the time of vaccination.Results. Both vaccines were well tolerated by children aged 12 to 17 years and by children aged 6 to 12 years. There were no severe or serious adverse events. By all criteria of immunogenicity evaluation, vaccine Flu-M was not inferior to the comparison vaccine Ultrix.Conclusion. Influenza inactivated split Flu-M vaccine produced by SPbNIIVS is approved for use for specific prophylaxis of influenza in children aged 6 to 17 years in the Russian Federation, the Republic of Belarus, Latin America and the Caribbean.The trial is registered at ClinicalTrials. gov (NCT 05317767). |
| format | Article |
| id | doaj-art-eddccb212cd4466898dab14649fdb8ef |
| institution | Kabale University |
| issn | 2072-6732 |
| language | Russian |
| publishDate | 2024-04-01 |
| publisher | Journal Infectology |
| record_format | Article |
| series | Журнал инфектологии |
| spelling | doaj-art-eddccb212cd4466898dab14649fdb8ef2025-08-20T04:00:17ZrusJournal InfectologyЖурнал инфектологии2072-67322024-04-01161303810.22625/2072-6732-2024-16-1-30-381132Clinical trial of tolerability, safety and immunogenicity of influenza inactivated split-vaccine Flu-M in children aged 6 to 17 yearsA. M. Korolyuk0V. N. Kraeva1L. A. Zazimko2Yu. A. Koromzin3E. A. Ruzanova4N. N. Savina5E. V. Ryskova6Saint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations; Saint-Petersburg State Pediatric Medical UniversitySaint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial PreparationsSaint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial PreparationsSaint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial PreparationsSaint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial PreparationsSaint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial PreparationsSaint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial PreparationsPurpose. To evaluate the tolerability, safety and immunogenicity of influenza inactivated split flu vaccine Flu-M during single immunization of children aged 6 to 17 years.Materials and methods. A multicentre double-blind comparative randomised clinical trial of influenza inactivated split vaccine Flu-M for immunisation of children aged 6 to 17 years (the reference agent – Ultrix vaccine) was conducted. Children aged 12 to 17 years inclusive (300 children) were studied at stage I, and children aged 6 to 12 years (300 children) at stage II. Volunteers of each age category were randomised 1:1 into 2 groups comparable in sex and age, one was vaccinated with Flu-M vaccine and the other with Ultrix vaccine. The follow-up, including various laboratory and clinical tests, lasted for 28 days from the time of vaccination.Results. Both vaccines were well tolerated by children aged 12 to 17 years and by children aged 6 to 12 years. There were no severe or serious adverse events. By all criteria of immunogenicity evaluation, vaccine Flu-M was not inferior to the comparison vaccine Ultrix.Conclusion. Influenza inactivated split Flu-M vaccine produced by SPbNIIVS is approved for use for specific prophylaxis of influenza in children aged 6 to 17 years in the Russian Federation, the Republic of Belarus, Latin America and the Caribbean.The trial is registered at ClinicalTrials. gov (NCT 05317767).https://journal.niidi.ru/jofin/article/view/1605tolerabilitysafetyimmunogenicityflu-m and ultrix vaccineschildren 6 to 17 years of age |
| spellingShingle | A. M. Korolyuk V. N. Kraeva L. A. Zazimko Yu. A. Koromzin E. A. Ruzanova N. N. Savina E. V. Ryskova Clinical trial of tolerability, safety and immunogenicity of influenza inactivated split-vaccine Flu-M in children aged 6 to 17 years Журнал инфектологии tolerability safety immunogenicity flu-m and ultrix vaccines children 6 to 17 years of age |
| title | Clinical trial of tolerability, safety and immunogenicity of influenza inactivated split-vaccine Flu-M in children aged 6 to 17 years |
| title_full | Clinical trial of tolerability, safety and immunogenicity of influenza inactivated split-vaccine Flu-M in children aged 6 to 17 years |
| title_fullStr | Clinical trial of tolerability, safety and immunogenicity of influenza inactivated split-vaccine Flu-M in children aged 6 to 17 years |
| title_full_unstemmed | Clinical trial of tolerability, safety and immunogenicity of influenza inactivated split-vaccine Flu-M in children aged 6 to 17 years |
| title_short | Clinical trial of tolerability, safety and immunogenicity of influenza inactivated split-vaccine Flu-M in children aged 6 to 17 years |
| title_sort | clinical trial of tolerability safety and immunogenicity of influenza inactivated split vaccine flu m in children aged 6 to 17 years |
| topic | tolerability safety immunogenicity flu-m and ultrix vaccines children 6 to 17 years of age |
| url | https://journal.niidi.ru/jofin/article/view/1605 |
| work_keys_str_mv | AT amkorolyuk clinicaltrialoftolerabilitysafetyandimmunogenicityofinfluenzainactivatedsplitvaccinefluminchildrenaged6to17years AT vnkraeva clinicaltrialoftolerabilitysafetyandimmunogenicityofinfluenzainactivatedsplitvaccinefluminchildrenaged6to17years AT lazazimko clinicaltrialoftolerabilitysafetyandimmunogenicityofinfluenzainactivatedsplitvaccinefluminchildrenaged6to17years AT yuakoromzin clinicaltrialoftolerabilitysafetyandimmunogenicityofinfluenzainactivatedsplitvaccinefluminchildrenaged6to17years AT earuzanova clinicaltrialoftolerabilitysafetyandimmunogenicityofinfluenzainactivatedsplitvaccinefluminchildrenaged6to17years AT nnsavina clinicaltrialoftolerabilitysafetyandimmunogenicityofinfluenzainactivatedsplitvaccinefluminchildrenaged6to17years AT evryskova clinicaltrialoftolerabilitysafetyandimmunogenicityofinfluenzainactivatedsplitvaccinefluminchildrenaged6to17years |